Results 51 to 60 of about 9,288,830 (350)
Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event.
Yohana Azhar +3 more
doaj +1 more source
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC).
G. Sledge +17 more
semanticscholar +1 more source
Glucocorticoids (GCs) are widely prescribed for their anti-inflammatory and immunosuppressive properties as a treatment for a variety of diseases. The use of GCs is associated with important side effects, including diabetogenic effects.
Etienne Delangre +8 more
doaj +1 more source
Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resistance to endocrine therapy is a major health concern among hormone-positive breast cancer patients.
Jie Yuan +11 more
doaj +1 more source
Purpose: There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2 ...
X. Hua +21 more
semanticscholar +1 more source
Significance Resistance to endocrine therapy is a major obstacle to managing breast cancer. Here, we introduce that tripartite motif protein TRIM47 enhances endocrine therapy resistance and facilitates breast cancer tumorigenesis.
Kotaro Azuma +5 more
semanticscholar +1 more source
Endocrine therapy regimen intensity according to EPclin.
Endocrine therapy regimen intensity according to EPclin.
Veronica Bautista-Piña (177269) +11 more
core +1 more source
Endocrine therapy is the gold-standard treatment for ER-positive/HER2-negative breast cancer. Although its clear benefit, patient compliance is poor (50–80%) due to its long administration period and adverse effects.
Li Yan +6 more
core +1 more source
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
BACKGROUND An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in
S. Im +18 more
semanticscholar +1 more source
Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide.
I. Barone +6 more
semanticscholar +1 more source

